Registre des actions collectives

Aperçu de la demande d’action collective 500-06-000512-109

Impression de l'aperçu de la demande d'action collective

Étape de la demande :

Autorisation - Demande d’autorisation pour exercer l’action collective à la Cour supérieure

Palais de justice :

Montréal

Date de dépôt de la demande d'autorisation :

2010-07-16

No de dossier :

500-06-000512-109

Sujet :

Protection du consommateur; Protection du consommateur

Cette affaire concerne :

Nom des parties :

Yann Lebrasseur vs. Hoffmann-La Roche Limitée

Description du groupe qui intente l'action :

SUB-GROUP A: All persons in Canada (including their estates, executors, or personal representatives), who have ingested prescription medications containing an ingredient called Isotretinoin, manufactured, marketed or distributed by the Respondent, and who claim that they have suffered or are suffering from bowel injuries such as Crohn’s disease, ulcerative colitis, proctitis, inflammatory bowel disease (IBD), rectal bleeding and ileitis as a result of ingesting said prescription medications; SUB-GROUP B: All persons in Canada (including their estates, executors, or personal representatives), who have ingested prescription medications containing an ingredient called Isotretinoin, manufactured, marketed or distributed by the Respondent, and who claim that they have suffered or are suffering from any and all other side effects (not listed in Sub-Group A above), including but not limited to pancolitis, abdominal cramping and pain, pseudotumor cerebri of central nervous system (benign intracranial hypertension, intracranial hypertension), bone and muscle damage, hearing and vision impairment, liver damage, pancreatitis (including hemorrhagic pancreatitis), lupus, immunodeficiency (deficiency of immune system), glomerulonephritis (inflammatory disease of the kidneys), psychiatric side effects such as suicide, suicidal thoughts, suicide attempts, depression, aggression, paranoia, violent behaviors, psychosis, changes in personality, mood swings, withdrawal and abnormal behaviors, and birth defects; or any other Group or Sub-Group to be determined by the Court.

Documents et actes de procédure :

Document Date du document
Demande d’autorisation d’exercer une action collective 2010-07-16
Réponse 2010-08-10

Avocats de la partie demanderesse :

Nom Courriel Téléphone Adresse Nom du cabinet Site web
Chung, Daniel [email protected] (514)842-7776 10 Notre-Dame Est, Suite 200, Montreal, Québec, Canada , H2Y 1B7 Merchant Law Group www.merchantlaw.com

Avocats de la partie défenderesse :

Nom Courriel Téléphone Adresse Nom du cabinet
Loranger, Julie Martine (514)392-9552 1 place Ville Marie, 37ème étage, Montréal, Québec, Canada , H3B 3P4 Gowling Lafleur Henderson LLP

Étape de la demande

1 - Autorisation - Demande d’autorisation pour exercer l’action collective à la Cour supérieure

Palais de justice

Montréal

Date de dépôt de la demande d'autorisation

2010-07-16

No de dossier

500-06-000512-109

Sujet

Protection du consommateur; Protection du consommateur

Cette affaire concerne

Nom des parties

Yann Lebrasseur vs. Hoffmann-La Roche Limitée

SUB-GROUP A: All persons in Canada (including their estates, executors, or personal representatives), who have ingested prescription medications containing an ingredient called Isotretinoin, manufactured, marketed or distributed by the Respondent, and who claim that they have suffered or are suffering from bowel injuries such as Crohn’s disease, ulcerative colitis, proctitis, inflammatory bowel disease (IBD), rectal bleeding and ileitis as a result of ingesting said prescription medications; SUB-GROUP B: All persons in Canada (including their estates, executors, or personal representatives), who have ingested prescription medications containing an ingredient called Isotretinoin, manufactured, marketed or distributed by the Respondent, and who claim that they have suffered or are suffering from any and all other side effects (not listed in Sub-Group A above), including but not limited to pancolitis, abdominal cramping and pain, pseudotumor cerebri of central nervous system (benign intracranial hypertension, intracranial hypertension), bone and muscle damage, hearing and vision impairment, liver damage, pancreatitis (including hemorrhagic pancreatitis), lupus, immunodeficiency (deficiency of immune system), glomerulonephritis (inflammatory disease of the kidneys), psychiatric side effects such as suicide, suicidal thoughts, suicide attempts, depression, aggression, paranoia, violent behaviors, psychosis, changes in personality, mood swings, withdrawal and abnormal behaviors, and birth defects; or any other Group or Sub-Group to be determined by the Court.
Retour